MeToo i would have to agree with your comments about Mr Byrd, as...

First 22 Last

Share
Profile

Follow
trumpy71

2,367 Posts.

22

14/10/15

16:26

Post #: 16176165
Share

Originally posted by MeToo ↑

Hi MACCA, sometimes I think that you have a background in Public Relations (spin)
Anyway we seem to be on a non stop merry go round at the moment.

By the way, what I do with my time and what interests I have is up to me. Also you are not "entertaining me" and I do not care if you reply. If you would prefer I will not use the "reply with quote" function. But if I do then posts can get very confusing when trying to follow a conversation.

You, me and anyone else can post what ever we like as long as it is stays within the HC rules and by posting we must expect the that our posts are open to scrutiny by anyone.

Mr. "Byrd" would, in my opinion have to be quite a big holder to know "that an announcement will arrive next week on progress.” [your words] Especially when "the announcement" released by the ASX is taken in context, as a reply to a "please explain" from the ASX.

I have read some of your other posts, so you want to talk about ego?

Note - I really do believe in the potential for marijuana in the medical world, although in saying that, there are the problems of who is in bed with who, who has potential and who is real.

I am not sure (undecided) about legalizing pot for stoners and the general public, it could eventually open a whole new world of associated problems.

END of rant.

Expand

MeToo i would have to agree with your comments about Mr Byrd, as a CTR share holder with close to 9M shares ( first purchased at 0.028 ) i used to contact OKAP ( CTR management ) and direct questions at them to which most of the replies ( announcement soon, O & G expert to be appointed to the board shortly etc ... ) never came to fruition and were just the easy way to get me off the phone or out of the office.

IGS Price at posting: 0.2¢ Sentiment: Sell Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

TI1

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The iron ore comeback: Can it last?

HAW

Hastings progressing Yangibana to production with lower costs

ZNO

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%